SOLID-TIMI 52

SOLID-TIMI 52 was a randomized, double-blind, placebo-controlled trial to assess the efficacy of darapladib, a novel Lp-PLA2 inhibitor, when added to standard of care in high-risk patients stabilized after ACS.

Screenshot_2021-02-03 PowerPoint Presentation - timi-52-slides pdf

MAIN RESULTS:
Rivaroxaban in patients with a recent acute coronary syndrome
SOLID-TIMI 52
N Engl J Med. 2012 Jan 5;366(1):9-19.

PRESENTATIONS

TIMI 52 Slides
SOLID Ceramides (Gencer, AHA 2019)
A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease (Patel, AHA 2020)
Clinical Applications of a Polygenic Risk Score to Predict Atrial Fibrillation in Patients with Cardiometabolic Disease (Garfinkel, AHA 2021)
A Genetic Risk Score to Predict Peripheral Artery Disease and Acute Limb Ischemia in Patients With Cardiometabolic Disease (Patel, AHA 2021)

OTHER PUBLICATIONS

Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011 Oct;162(4):613-619.e1.

Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events. Cardiol Ther. 2013 Dec; 2(2): 125–134.

Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. J Am Heart Assoc. 2017 Jan 11;6(1):e004332.

Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017 Mar 28;69(12):1549-1559. 

Interleukin-6 And The Risk Of Adverse Outcomes In Patients After An Acute Coronary Syndrome: Observations From The SOLID-TIMI 52 Trial. J Am Heart Assoc. 2017 Oct 24;6(10):e005637.

Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. Eur J Prev Cardiol. 2018 May;25(8):830-838.

Metabolic Syndrome And The Risk Of Adverse Cardiovascular Events After An Acute Coronary Syndrome: Insights From SOLID-TIMI 52 Trial. Eur J Prev Cardiol. 2018 May;25(8):830-838.

Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 Jun 1;3(6):473-480.

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome. J Am Heart Assoc. 2018 Oct 16;7(20):e009077.

Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 Nov 7;39(42):3810-3820.

Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 Dec 17;74(24):3013-3022.

Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwaa143. Published: 29 December 2020.

Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 Feb 16;143(7):685-695.

 

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close